Delving into the Latest Updates on Ceftibuten/Clavulanate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

C-Scape, Ceftibuten/clavulanic acid, Ceftibuten/clavulanic-acid

+ [4]

Target

PBPs

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Achaogen, Inc.

Active Organization-

Inactive Organization

Achaogen, Inc.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC8H9NO5

InChIKeyHZZVJAQRINQKSD-PBFISZAISA-N

CAS Registry58001-44-8

View All Structures (2)

Ceftibuten-clavulanate (CTB-CLA) is a novel β-lactam–β-lactamase combination with potential utility for the management of urinary tract infections caused by extended-spectrum-β-lactamase (ESBL)-producing organisms. We examined the pharmacodynamics of the combination against 25 Enterobacteriaceae expressing β-lactamases (CTX-M, TEM, and SHV wild types and SHV-ESBL) in the murine thigh infection model.

01 Jan 1990·Tsitologiia

[The characteristics of the localization of induced ruptures in human chromosomes].

Article

Author: Druzhinin, V G

Levels of spontaneous and of C-mitomycine and cyclophosphane-induced chromosome aberrations are determined among the persons not subject to professionally industrial hazards. It has been revealed that in all the experimental series the aberration rate in those, who carried extreme polymorphic variants, was much higher compared to those without these variants in their karyotypes. Among the persons with the above extreme versions, the impact of chromosome ruptures is stronger in the vicinity of the structural heterochromatin. Possible causes of the discovered phenomenon are discussed.

100 Deals associated with Ceftibuten/Clavulanate

Login to view more data